A proteomic landscape of diffuse-type gastric cancer.
Sai GeXia XiaChen DingBei ZhenQuan ZhouJinwen FengJiajia YuanRui ChenYumei LiZhongqi GeJiafu JiLianhai ZhangJiayuan WangZhongwu LiYumei LaiYing HuYanyan LiYilin LiJing GaoLin ChenJianming XuChunchao ZhangSung Yun JungJong Min ChoiAntrix JainMingwei LiuLei SongWanlin LiuGaigai GuoTongqing GongYin HuangYang QiuWenwen HuangTieliu ShiWeimin ZhuYi WangFuchu HeLin ShenJun QinPublished in: Nature communications (2018)
The diffuse-type gastric cancer (DGC) is a subtype of gastric cancer with the worst prognosis and few treatment options. Here we present a dataset from 84 DGC patients, composed of a proteome of 11,340 gene products and mutation information of 274 cancer driver genes covering paired tumor and nearby tissue. DGC can be classified into three subtypes (PX1-3) based on the altered proteome alone. PX1 and PX2 exhibit dysregulation in the cell cycle and PX2 features an additional EMT process; PX3 is enriched in immune response proteins, has the worst survival, and is insensitive to chemotherapy. Data analysis revealed four major vulnerabilities in DGC that may be targeted for treatment, and allowed the nomination of potential immunotherapy targets for DGC patients, particularly for those in PX3. This dataset provides a rich resource for information and knowledge mining toward altered signaling pathways in DGC and demonstrates the benefit of proteomic analysis in cancer molecular subtyping.
Keyphrases
- cell cycle
- end stage renal disease
- immune response
- data analysis
- ejection fraction
- newly diagnosed
- chronic kidney disease
- healthcare
- signaling pathway
- cell proliferation
- peritoneal dialysis
- squamous cell carcinoma
- patient reported outcomes
- single cell
- oxidative stress
- dna methylation
- risk assessment
- toll like receptor
- inflammatory response
- single molecule
- social media
- rectal cancer
- locally advanced
- free survival
- human health
- patient reported
- induced apoptosis
- label free